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EDITORIAL REVIEWS 
Reperfusion Momentum: Lessons From the Randomized Trials of 
Immediate Coronary Angioplasty for Myocardial Infarction* 
DAVID R. HOLMES, JR., MD, FACC, ERIC J. TOPOL, MD, FACC 
Rochester, Minnesota and Ann Arbor, Michigan 
Evolution of treatment strategies follows a typical course, 
which begins with recognition of a clinical problem, charac- 
terization of the anatomic and pathophysiologic mechanisms 
involved and attempts to identify treatments. This evolution 
culminates in randomized trials that often compare one of 
several strategies with placebo controls. This course has 
been followed in the field of reperfusion therapy for acute 
myocardial infarction (1-18). Early descriptions of success- 
ful thrombolytic therapy through an intracoronary and then 
an intravenous route culminated in several randomized trials 
that documented improved survival with one of several lytic 
therapies (l-3,5,7,8). 
Role and Timing of Coronary Dilation 
The proper role and timing of dilation have been more 
difficult to define. Percutaneous transluminal coronary an- 
gioplasty can play several roles. It can be used as the sole 
means of reperfusion or it can be used in combination with 
lytic therapy-either if lytic therapy fails or if a significant 
residual stenosis remains. Given the urgency for achieving 
early reperfusion and the limited access to hospitals with 
facilities and trained personnel that are available 24 h/day, 
angioplasty as the sole means of reperfusion is not the 
solution for most patients during acute myocardial infarc- 
tion. Instead, from a national health care planning stand- 
point, there has been intense interest in identifying the role 
and timing of coronary angioplasty after lytic therapy for 
acute myocardial infarction. Recently, three large random- 
ized trials-Thrombolysis in Myocardial Infarction (TIM1 II) 
(19), Thrombolysis and Myocardial Infarction (TAMI) (16) 
and European Cooperative Study Group (18)-that address 
this important topic have been concluded. Although these 
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three studies do not answer all of the questions about the 
ideal agent to be used or the strategy to use if thrombolysis 
does not work, they have resulted in an unusual degree of 
consensus. 
Study Goals and Design 
Eligibility and inclusion criteria. These were similar for 
each trial (Table 1) and included patients ~70 to 75 years of 
age with chest pain for at least 20 to 30 min in association 
with ST segment elevation 20.1 mV in whom the time from 
onset to the initiation of treatment was less than 4 to 5 h. The 
European Cooperative Study Group trial (18) did include 
patients with cardiogenic shock, whereas the TAM1 trial (16) 
excluded them. In each study, recombinant tissue plasmino- 
gen activator @t-PA) (usual dose 100 mg) was the throm- 
bolytic agent (Table 2). 
Adjunctive therapy. This was similar in the three studies. 
All three trials included heparin and aspirin given in some- 
what different regimens. Intravenous aspirin was given early 
in the European trial, whereas the oral preparation, admin- 
istered within 24 to 48 h, was given in the others. The TAM1 
trial withheld heparin given as a bolus until 90 min after 
administration of rt-PA; in the other two trials, these agents 
were given in combination. 
Goals and objectives. The goals of these studies facilitate 
the comparisons and consensus reached (Table 2); each 
allowed comparison of a strategy of immediate angioplasty 
with delayed angioplasty or no angioplasty after administra- 
tion of rt-PA for acute infarction. All three studies used 
global left ventricular function as the primary end point on 
which to base calculated sample sizes. In addition, the 
European Cooperative Study Group used enzymatic assess- 
ment of infarct size. Secondary end points included clinical 
outcome, death, recurrent infarction and angioplasty per- 
formance. 
The specific objective of the TIMI ZIA trial (19) was to 
compare 2 h angioplasty with 18 h to 48 h angioplasty after 
thrombolytic therapy for acute infarction, and the purpose of 
the TAM1 study (16) was to determine the relative clinical 
benefits of coronary angioplasty performed immediately 
compared with those of elective angioplasty performed after 
successful thrombolysis. For the European Cooperative 
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Table 1. Inclusion Criteria for Three Studies of Coronary Table 3. Data for Coronary Angioplasty Randomization in Three 
Thrombolysis for Acute Myocardial Infarction Studies of Thrombolysis for Acute Myocardial Infarction 
Study 
TIM1 IIA TAM1 ECSG 
Duration of chest pam (mm) 230 220 230 
Age (yrl <I6 c75 <71 
Time to treatment (hi 54 <4* <5 
ECG ST elevation >O.l (mV) 21 (mm) >0.1-0.3 (mV)t 
*Or if ongoing chest pain had been present <6 h. Wariability depended on 
location of elevation. ECG = electrocardiographic; ECSG = European 
Cooperative Study Group (18): TAMI = Thrombolysis and Myocardial 
Infarction trial (16): TIMI IIA = Thrombolysis in Myocardial Infarction IIA 
trial (191. 
Study Group, the primary objective was to determine 
whether an invasive strategy combining thrombolysis with 
r&PA, heparin and aspirin with immediate angioplasty is 
superior to a noninvasive strategy with the same medical 
regimen but without immediate angiography and angio- 
plasty. 
Differences in randomization. It is important to note that 
randomization to early angioplasty was performed before 
angiography in the TIM1 study and the European Coopera- 
tive study. This protocol contrasts with the TAMI study, in 
which randomization to immediate angioplasty was done 
only after coronary angiography. In the TAM1 trial, patients 
with persistent occlusion were not randomized to either 
immediate or delayed angioplasty. A total of 1,142 patients 
were entered in the three studies: 389 in the TIM1 IIA trial, 
386 in the TAM1 study and 367 in the European Cooperative 
Study Group (Table 2). Although 1,142 patients were en- 
tered, the number of patients in whom dilation was actually 
attempted was considerably smaller (Table 3). 
The difference between the number of patients random- 
ized to dilation and those in whom dilation was attempted 
reflects the angiographic criteria for immediate angioplasty 
(Table 4). According to their randomized schemes, the TIM1 
IIA and European Cooperative Study Group trials treated 
Table 2. Strategies for Three Studies of Thrombolysis for Acute 
Mvocardial Infarction 
Study 
No. of Dose of Cardiac 
Patients rt-PA (mg) Catheterization IWA 







Immediate vs. Immediate vs. 
18 to 48 h 18 to 48 h 
Immediate Immediate vs. 
7 days 
Immediate vs. Immediate vs. 
before discharge none 
*The first one-third of the patients received 150 mg; this dose was 
subsequently changed to 100 mg. PICA = percutaneous transluminal coro- 
nary angioplasty; rt-PA = recombinant tissue plasminogen activator; other 
abbreviations as in Tables I and 2. 
TIM1 IIA TAM1 ECSG 
PICA 
at PTCA at Immediate Elective Immediate No 
2h 18to48h PTCA PICA PICA PTCA 








*Sixteen additional patients randomized to elective angioplasty had urgent 
angioplasty by crossover before timing of elective angioplasty. Abbreviations 
as in Tables 1 and 2. 
patients whose infarct-related artery was found to be oc- 
cluded after thrombolytic therapy, whereas the TAM1 study 
did not randomize these patients. In addition, the TIM1 IIA 
trial had several anatomic descriptors that resulted in exclu- 
sion. 
Results of Dilation 
Definitions of success. The outcome of angioplasty varied, 
depending in part on the definition of success that was used. 
For the TIM1 IIA trial, full improvement or complete suc- 
cess required an absolute reduction in the luminal stenosis of 
~20% and a final residual infarct-related arterial stenosis 
~60%. In addition, flow in the infarct-related artery had to 
be normal or improved after the procedure. Partial improve- 
ment included at least one of the changes in stenosis severity 
(that is, ~20% reduction or a final stenosis ~60%) with 
either no change or an improvement in flow. For the TAM1 
study, complete success was defined as a residual stenosis 
~50% with normal anterograde flow. A partial success was 
defined as some improvement in stenosis but a residual 
stenosis >50% at the end of the procedure. For the Euro- 
pean Cooperative Study Group trial, success was defined as 
improvement in quantitative stenosis severity after coro- 
nary angioplasty and an improvement in perfusion grade 
(6,15,18). 
Success rates. Within each study (Table 5) that compared 
immediate with delayed angioplasty, the success rates were 
increased with delayed elective angioplasty. In the TIM1 IIA 
study, dilation was successful in 84% of the patients who had 
immediate angioplasty and in 94% of those who had dilation 
at 18 to 48 h. In the TAM1 trial, 85% of the immediate 
angioplasty procedures were completely successful, and 
94% of the elective procedures were successful. It must be 
remembered that the proportion of patients initially assigned 
to late elective angioplasty who actually had dilation de- 
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Table 4. Angiographic Criteria for Exclusion From Immediate Coronary Angioplasty in Three 
Studies of Thrombolvsis for Acute Mvocardial Infarction 
TIMI IIA TAM1 ECSG 
Residual stenosis ~60% 
Unsuitable features 
Lesions 220 mm 
Major bifurcation involved 
Distal lesion 
Tortuous proximal vessel 
If sudden occlusion would 
cause “catastrophic 
consequences” 
Occluded infarct-related artery 
Unsuitable features 
Residual stenosis <SO% 
Stenosis in LMCA >50% 




No significant lesion 
Unsuitable for PTCA 
Left main equivalent 
Three-vessel disease 
No infarct-related artery 
apparent 
LMCA = left main coronary artery; other abbreviations as in Tables I and 2. 
creased with time for various reasons: pronounced resolu- 
tion of the lesion so that angioplasty was no longer required; 
reocclusion, which was either silent or required an urgent 
intervention (angioplasty or coronary artery bypass graft- 
ing); or case selection (Fig. 1). 
In the European Cooperative Study Group trial, success 
rates in the immediate angioplasty group are more difficult to 
assess. Ninety percent of patients undergoing immediate 
angioplasty had a patent infarct-related artery after dilation 
with stenosis of ~91%. However, 61% of the patients had a 
residual diameter stenosis of ~50%. Dilation was attempted 
in most patients (92%) unless the initial stenosis was ~60%. 
This strategy contrasts with the TIM1 and TAMI studies, in 
which angioplasty was not performed if the lesion was 
unfavorable (Table 4), such as stenosis in the left main 
coronary artery >50% or its equivalent, severe, diffuse 
disease or an artery that remained occluded after thrombol- 
ysis. This difference in study design may, in fact, account for 
the differences in success rates. 
Irrespective of these differences, success rates were 
increased in patients who underwent an elective dilation 
procedure. In addition, in the TAM1 trial, abrupt vessel 
reclosure and the need for emergency coronary artery by- 
pass grafting in association with dilation were less with 
elective dilation procedures. In the TIM1 IIA study, the need 
for bypass grafting was higher in the group with immediate 
angioplasty (4.3%) than in the group with delayed angio- 
plasty (1.9%). 
Table 5. Outcome of Coronary Angioplasty in Three Studies of 
Thrombolysis for Acute Myocardial Infarction 
TIM1 HA TAMI ECSG 
FTCA at PICA at Immediate Elective Immediate 
2h 18 to 48 h PTCA PTCA PTCA 
(n =141) (n = 107) (n = 99) (n = 35) (n = 168) 
Successful (%) 84 92 85 94 90 
Abbreviations as in Tables 1 and 2. 
Outcome 
Left ventricular function. Left ventricular function was 
assessed in each group (Table 6). Initial experience in other 
randomized trials (14) with smaller numbers of patients had 
documented improvement with angioplasty in comparison 
with conventional lytic therapy. In the three trials, however, 
no significant difference was found in the predischarge global 
ejection fraction between the immediate angioplasty group 
and the other treatment group (Table 6). In addition, al- 
though the TAM1 study noted significant improvement in 
regional wall motion in the infarct artery distribution from 
baseline to dismissal in both the immediate and the elective 
angioplasty groups, the degree of improvement was similar 
Figure 1. Outcome of patients with a tight residual infarct vessel 
stenosis after intravenous thrombolytic therapy in the TAM1 trial. 
Although 98 patients were assigned to a deferred angioplasty strat- 
egy and were found to be suitable for this at the immediate phase 
catheterization, only 35% of patients actually had angioplasty at 7 
days as planned. An important group of patients were the 14% who 
had significant regression of the infarct vessel stenosis; if these 
patients had undergone acute phase angioplasty, they would have 
been exposed unnecessarily to the hazards associated with this 
procedure. Another important group of patients were the 11% who 
underwent elective coronary artery bypass grafting (CABG) rather 
than angioplasty when their cases were reviewed after the emer- 
gency catheterization. ETT = exercise treadmill test; F’TCA = 
percutaneous transluminal coronary angioplasty. 
” 
Ektiive NegElthre Urgent Regressicn Elective 
PTCA Eli PTCA/CABQ IO <K% CAB0 
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Table 6. Left Ventricular Function and Mortality in Three Studies of Thrombolysis for Acute 
Myocardial Infarction 
TIM1 IIA TAM1 ECSG 
Immediate PTCA at Immediate Elective Immediate Noninvasive 
PTCA 18 to 48 h PTCA PICA PTCA PTCA 
(n = 195) (tl = 194) (n = 99) (n = 98) (n = 183) (n = 184) 
Discharge LVEF (‘%) 50 49 53 56 51 51 
p value 0.08 
Mortality (in-hospital) (%) 7.2 5.1 4 1 1* 3* 
p value 0.54 0.37 0.04 
LVEF = left ventricular ejection fraction; other abbreviations as in Tables 1 and 2. *The mortality at 14 days was 
7% for the invasive group and 3% for the noninvasive group. At 3 months, the mortality rate was 8% and 3%, 
respectively, for these two groups. 
for each group. It must be kept in mind that left ventricular 
function was assessed generally at 7 to 10 days after the 
onset of infarction. This interval is probably too short a time 
to determine the full potential benefits of reperfusion, which 
may take a matter of weeks. 
Mortality. Mortality was not the primary end point in any 
of the three study designs because the projected numbers of 
patients were thought to be too small. In each of the three 
studies, however, mortality in the elective angioplasty group 
(or in the noninvasive group of the European Cooperative 
Study Group) was less than that in the immediate angio- 
plasty group: 5.7% versus 7.2% for the TIM1 IIA trial, 1 .O% 
versus 4.0% for the TAM1 study and 3.0% versus 7.0% (p = 
0.04) for the European Cooperative Study Group (Table 6). 
Other end points. In addition to left ventricular function 
and mortality, other end points were also assessed: bleeding 
requiring transfusion, reinfarction, reocclusion and emer- 
gency coronary artery bypass grafting (Table 7). For some of 
these end points, data were available from only two of the 
three studies. For each end point, the immediate angioplasty 
group had a higher incidence of complications, except in the 
European Cooperative Study Group, in which the noninva- 
sive group had a slightly increased incidence of reinfarction 
compared with that in the immediate angioplasty group. 
Conclusions From These Trials and 
Implications for Practice 
The conclusions reached from these three studies were 
remarkably similar. In the TIM1 IIA trial (19), “immediate 
coronary angiography and angioplasty did not offer any 
advantage over the strategy of deferring these procedures 18 
to 48 hours after the administration of recombinant tissue 
plasminogen activator.” The TAM1 study (16) concluded 
that “with initially successful thrombolysis with recombi- 
nant tissue plasminogen activator and suitable coronary 
artery anatomy, immediate angioplasty offers no clear ad- 
vantage over delayed angioplasty.” The European Cooper- 
ative Study Group (18) reported that immediate angioplasty 
Table 7. Clinical Outcome and Complications in Three Studies of Thrombolysis for Acute Myocardial Infarction 
TIMI IIA TAM1 ECSG 
Immediate 18 to48 h Immediate Elective Immediate Noninvasive 
PTCA PICA PTCA PICA PTCA PICA 




CABG within 24 h 
of PTCA (%) 
20.0 7.2* IO 4 
6.7 4.1 4 7t 
PW 
11 13 12.5 11 
(NS) (NS) 
4.3 1.9 I$ 2$ 
*Transfusion of >l unit (p < 0.001). tAlthough reinfarction was slightly higher in the noninvasive group, when recurrent ischemia within 24 h of initial 
presentation was analyzed, the invasive group had a higher incidence (17%) than the noninvasive group (3%). fEmergency CABG (p = 0.17). CABG = coronary 
artery bypass grafting: NS = not significant; other abbreviations as in Tables I and 2. 
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did not provide additional benefit in patients with acute 
myocardial infarction treated with rt-PA. 
Clinical implications. Given the time, effort and re- 
sources expended, the importance of the problem and the 
randomized well designed structure, it is hoped that these 
trials can be used to modify our practice. It must be kept in 
mind that these trials deal only with the combined use of 
angioplasty and rt-PA. The unique interaction, either posi- 
tive or negative, between these two treatments may or may 
not be equivalent to that of other combinations. Indeed, 
larger randomized trials are under way to study urgent 
angioplasty in combination with other lytic regimens such as 
r&PA and urokinase, or angioplasty and anisoylated strep- 
tokinase, or angioplasty and streptokinase to determine 
whether some of the complications in the immediate angio- 
plasty group can be decreased. 
Irrespective of that, one major conclusion can be 
reached: if r&PA is selected as the initial therapy in a patient 
with acute myocardial infarction, subsequent therapy should 
not incorporate routine urgent angioplasty. Indeed, delayed 
angioplasty after this thrombolytic therapy is preferable 
because the complication rate is lower and the outcome 
seems to be improved. The importance of this concept is 
strengthened further by the lack of benefit in terms of 
improved left ventricular function at rest in the immediate 
angioplasty group and the finding from other studies that 
delayed angioplasty can still result in improved exercise left 
ventricular function (20). Delaying angioplasty after lytic 
reperfusion also may allow some healing of the unstable 
local arterial pathologic change that was responsible for the 
initial thrombosis and infarction. 
Unsuccessful thrombolysis with ongoing ischemia. In ad- 
dition to this conclusion, there are some other implications. 
These primary trials do not specifically consider patients 
with unsuccessful lytic therapy and ongoing ischemia. Reli- 
able noninvasive recognition of these patients usually has 
not been possible (21). In such patients, the outcome is 
worse (16,22). Attempts at salvage or rescue angioplasty or 
coronary artery bypass grafting are reasonable to limit 
infarct size and improve outcome. Future studies will focus 
on this group of patients, which constitutes approximately 
25% of all patients with acute myocardial infarction who are 
given rt-PA but do not exhibit reperfusion in the first 2 h after 
therapy. 
Successful reperfusion and subsequent reocclusion. A sec- 
ond implication not specifically addressed but implicit is 
development of the optimal strategy in patients with success- 
ful initial reperfusion but subsequent clinical reocclusion. In 
these patients, in whom the initial decision was to treat the 
infarction aggressively, it makes intuitive sense that, if 
reocclusion is suspected, urgent angiography and reperfu- 
sion with either angioplasty or coronary artery bypass 
grafting are indicated in an attempt to prevent reinfarction, if 
possible. 
Need for Urgent Coronary Angiography 
An equally important point is the need for urgent routine 
angiography. Its use has the advantage that patients in whom 
lytic therapy fails can be identified correctly and other 
treatment strategies used. Also, patients who need early 
operation, such as those with left main coronary artery 
stenosis, can be identified promptly. 
Disadvantages. There are, however, several disadvan- 
tages to urgent angiography. First, the cost is substantial 
because attempts need to be made for rapid access to a 
catheterization laboratory 24 h a day. This is not possible 
given current space, equipment and manpower consider- 
ations. Second, urgent angiography carries with it the need 
for intraarterial entry. Even when this procedure is per- 
formed with a small SF or 6F catheter, it greatly increases 
bleeding. Nearly all of the bleeding in the three studies was 
related to bleeding at the catheterization site. The third 
disadvantage is harder to quantitate, but it deals with the 
concept of “reperfusion momentum.” When the anatomy is 
documented urgently, patients may undergo dilation or be 
referred for operation earlier than is needed and the chance 
of complications is increased. Given the continued resolu- 
tion of the “stenosis” (presumably thrombus) that may 
occur in the first several days after lytic therapy, some 
patients might undergo urgent angioplasty for a lesion that is 
mainly thrombus without a significant underlying residual 
stenosis. Indeed, in the TAM1 trial (16), 14% of patients with 
a critical stenosis at 90 min after thrombolytic therapy had a 
lesion of ~50% by 7 days. 
Need for Elective Coronary Angioplasty 
The three trials of immediate coronary angioplasty ad- 
dressed the preferred timing of angioplasty but did not 
resolve the question of whether there is a need for routine 
predischarge angioplasty. The recent TIM1 II trial (23) 
focused on this important question. In this trial, 3,262 
patients treated with intravenous t-t-PA within 4 h of the 
onset of acute myocardial infarction were randomized to 
either 1) an invasive strategy consisting of catheterization 18 
to 48 h after admission and dilation (if suitable), or 2) a 
conservative strategy that did not include any angiography 
or dilation unless there was spontaneous or exercise-induced 
ischemia. The primary end point was survival free of recur- 
rent myocardial infarction at 42 days; secondary end points 
were left ventricular function at rest and exercise and 
recurrent ischemic events. In this large multicenter trial, the 
primary end points of death or recurrent infarction did not 
differ between the invasive and conservative strategy 
groups, nor were there any differences between the two 
groups in ejection fraction at rest or exercise at the time of 
hospital discharge or 6 weeks after discharge. Patients in the 
conservative strategy group did, however, have a higher 
JACC Vol. 14, No. 6 HOLMES AND TOPOL 
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incidence of a positive exercise test (17.7%) than did those in 
the invasive strategy group (12.8%) (p < 0.001). 
Implications. Thus, the results of the TIMI II trial (23) 
serve as a significant expansion of the lessons learned from 
the trials of immediate angioplasty. The concept of avoiding 
reperfusion momentum in performing immediate dilation 
was carried a major step further in that prophylactic routine 
and elective angioplasty also can be avoided. Revasculariza- 
tion with angioplasty or coronary artery bypass grafting 
therefore can be reserved for patients with recurrent isch- 
emia. 
accepted as standard therapy for acute myocardial infarc- 
tion. Knowing when to hold back and avoid “reperfusion 
momentum” is as important as knowing when and how to 
proceed. 
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